We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
In the latest market close, Viking Therapeutics, Inc. (VKTX - Free Report) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq increased by 0.7%.
Prior to today's trading, shares of the company had lost 8.84% over the past month. This has lagged the Medical sector's gain of 0.52% and the S&P 500's loss of 5.56% in that time.
Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.34, showcasing a 30.77% downward movement from the corresponding quarter of the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 10.65% lower. Viking Therapeutics, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 65, this industry ranks in the top 26% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the latest market close, Viking Therapeutics, Inc. (VKTX - Free Report) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. On the other hand, the Dow registered a gain of 0.52%, and the technology-centric Nasdaq increased by 0.7%.
Prior to today's trading, shares of the company had lost 8.84% over the past month. This has lagged the Medical sector's gain of 0.52% and the S&P 500's loss of 5.56% in that time.
Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.34, showcasing a 30.77% downward movement from the corresponding quarter of the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 10.65% lower. Viking Therapeutics, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 65, this industry ranks in the top 26% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.